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Dapsone is frequently effective in cutaneous diseases charac-
terized by antibody deposition and accumulation of neutro-
phils. We hypothesized that this mechanism of action of 
dapsone may involve the inhibition of neutrophil adherence 
to antibody. The neutrophil adherence assay, which mea-
sures the binding of neutrophils to basement membrane 
zone - bound antibody on skin sections, was used to evaluate 
the effect of dapsone on neutrophil adherence to immuno-
globulin A and immunoglobulin G. We evaluated the effect 
of dapsone on adherence of normal neutrophils to immuno-
globulin A and immunoglobulin G from sera oflinear immu-
noglobulin A bullous dermatosis and bullous pemphigoid 
patients, respectively. Linear immunoglobulin A bullous 
dermatosis or bullous pemphigoid antibody were bound to 
the basement membrane zone of normal skin sections as a 
substrate for the neutrophil adherence assay. Dapsone was 
D apsone (4,4'-diaminodiphenyl sulfone) is used for treatment of dermatitis herpetiformis (DH), but is also known to be effective in the therapy of a num-ber of cutaneous diseases that demonstrate deposi-tion of immunoglobulin (Ig) within the skin in com-
bination with the accumulation of neutrophils at the sight of tissue 
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Abbreviations: 
A TPBS: albumin Tris phosphate-buffered saline 
BMZ: basement membrane zone 
BP: bullous pemphigoid 
DH: dermatitis herpetiformis 
HBSS/HSA: Hanks' balanced salt solution/human serum albumin 
Ig: immunoglobulin 
IIF: indirect immunofluorescence 
LABD: linear IgA bul/ous dermatosis 
NAA: neutrophil adherence assay 
P AF: platelet-activating factor 
PBS: phosphate-buffered saline 
rGM-CSF: human recombinant granulocyte/macrophage 
colony-stimulation factor 
added directly to the neutrophi ls or to the antibody source in 
c~~centrations of 0 - 50 ,ug/ml (pharmacologic range). Ad-
~ltl?~ ?f dapsone to neutrophils produced an incremental 
mlubltlon of neutrophil adherence up to 75% at 50 ,ug/ml. 
Dapsone produced similar inhibition when added directly to 
the antibody itself, despite washing prior to usage in the 
neutrophil-adherence assay. Control specimens including ir-
relevant fractions of patient sera failed to demonstrate bind-
~ng: ~e~um from a patient on dapsone therapy also showed 
mh.lblt1on of neutrophil adherence compared to the same 
patient on no therapy. We conclude that dapsone inhibits the 
adherence of neutrophils to basement membrane zone anti-
body in a dose-dependent manner. This may be related to an 
effect directly on antibody. This inhibition may contribute to 
the clinical efficacy of dapsone in antibody-mediated dis-
eases.] Invest DermatoI100:349-355, 1993 
damage. These disorders include linear IgA bullous dermatosis 
(LABD), intraepidermal neutrophilic IgA dermatosis, chronic bul-
lous disease of ch.ildh?od, leukocytoclastic vasculitis, bullous lupus 
ery.thematosus. clcatnCla.1 pemphigoid, subcorneal pustular derma-
toSIS and bullous pemphigOid (BP) [1-14). The mechanism of ac-
tion of dapsone in these disorders is unclear. 
Dapsone has been shown to have an effect on various neutrophil 
functIOns such as myeloperoxidase-mediated iodination neutro-
~hil-lysosomal activity, and the generation of active oxyge~ metabo-
Ittes [15 - 19) .. H0.w~ver, the clinical response to dapsone is charac-
tenzed by the 111?lbltlon of accumulation of neutrophils in the skin, 
rather than the tissue accumulation of neutrophils that do not func-
tion c<:,r~ectly. ~l~erefore the role of these mechanisms in inhibiting 
the cluucal activity 111 these dermatoses is questionable. Dapsone 
does not appear to affect.neutrophil phagocytosis, antibody deposi-
tIOn 111 tIssue, serum antIbody levels, gluten-sensitive enteropathy, 
?r complement a~tivation [15,20 - 24). Dapsone has been shown to 
111hlblt neutropht! chemotaxis selectively induced by N-formyl-
methlOnyl-leucyl-phenylalanine, which is a bacterial product, but 
not by leukocyte-denved chemotactic factor, C5a, or normal 
human serum [15.25). The assessment of random motility is assay 
dep~~dent and therefore the published effect of dapsone on random 
mottltty has ?een reported to be both inhibitory and absent [15,26). 
Neutropl111s are known to have specific receptors for Fc portions 
of I&A. ~nd IgG [27 - 32). The neutrophil adherence assay (NAA) 
was Illltlal.ly used as a measure of the binding of neutrophils to IgG 
on BP sktn sections [33.34). With the addition of recombinant 
granulocyte macrophage colony stimulating factor (rGM-CSF) to 
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the NAA, Hendrix et al described the binding of neutrophils to IgA 
in both DH and LABD skin in vitro [35]. 
We have hypothesized that the mechanism of action of dapsone 
in the therapy of neutrophil-mediated dermatoses involves the inhi-
bition of neutrophil adherence to antibody in the skin. In the 
present investigation, we have evaluated the effect of dapsone on 
the adherence of normal neutrophils to antibasement membrane 
zone (BMZ) IgA and IgG from sera of LABD and BP patients. We 
present evidence that dapsone concentrations in the pharmacologic 
range inhibit neutrophil adherence to BMZ-bound LABD IgA and 
BP IgG in a dose-dependent manner. Moreover, we present eVI-
dence suggesting that dapsone may be exerting its effect on neutro-
phil adherence via a direct effect on IgA. 
METHODS 
Human Skin and Sera Normal human skin (cadaveric or abdo-
menoplasty) was obtained, keratomed to a thickness of 0.5 mm, 
washed in PBS, embedded in OCT compound (Miles Scientific, 
Naperville, IL), and stored at -70°C. Characteristics of sera from 
LABD and BP patients used for this study,were previously described 
[36,37] . LABD sera that contain only IgA, not IgG or IgM, and BP 
sera that contain IgG, not IgA or IgM, against the BMZ antigens 
were selected. LABD and BP sera had titers of anti-BMZ antibody 
detected by indirect immunofluorescence with human epidermis of 
1: 80 to 1: 160 and 1: 320 to 1: 5120 respectively. Normal human 
sera were obtained from blood bank donors. 
Neutrophil Preparation Neutrophils were prepared by the 
laboratory of Dr. Guy Zimmerman by the technique previously 
described [38]. Briefly, blood from healthy adult donors, who had 
abstained from use of alcohol, coffee, and medications for a mini-
mum of 72 h was drawn into heparinized syringes (7.5 units of 
heparin/ml blood). The heparinized ~lood was mixed with half of 
its volume of dextran (6% dextran 70111 0.9% NaCI). Erythrocytes 
were allowed to sediment for 60 min at room temperature. The 
supernatant, which was a leukocyte-rich plasma, was separated and 
centrifuged at 300 X g for 5 min at 4°C. After centrifugation in 
dextran, the erythrocyte contamination remaining in the leuko-
cyte-rich pellet was eliminated with hypotonic saline treatment 
(0.2% NaCI for 20 seconds then the same volume of 1.6% NaCI to 
the final concentration of 0.9% NaCI). The mixture was centri-
fuged again at 300 X g for 5 min at 4 ° C. The precipitated leukocyte 
pellet was resuspended in a solution o~ 0.20/? normal human serum 
albumin in Hanks' balanced salt solutIOn with human serum albu-
min (HBSS/HSA) and leukocytes were separated in a density-gra-
dient medium by introducing Ficoll-paque into the bottom of a tube 
containing the cell suspension (6 ml of Ficoll-paque into 5 ml of 
cell suspension) then centrifuged at 300 X g for 30 min at 4°C. 
Neutrophils were recovered from the pellets and then resuspended 
in HBSS/HSA. Harvested neutrophils were counted by a hemocy-
tometer under a light microscope and brought to a final concentra-
tion of 6.9 million cells/ml. This preparation routinely gave greater 
than 95% viability by neutrophil adhesion to a gelatin matrix. 
These neutrophils were used in the NAA immediately after isola-
tion. 
Isolation of Anti-97-kD LABD Antibody LABD antibody 
was isolated by using the 97 kD protein band on nitrocellulose 
Western blots ofLaemmli gels of epidermal extract as an immunoaf-
finity substrate as described previously [37]. Briefly, the 97 kD 
protein band on Western blots of epidermal extract was cut horizon-
tally and incubated for 5 h with LABD sera diluted 1 : 5 in albumin 
Tris phosphate-buffered saline (ATPBS), which consists of 0.5% 
BSA and 0.05% Tween-20 in PBS. After washing in ATPBS and 
deionized water for several changes, the antibodies were eluted in 
500 J.ll of 20 mM sodium citrate, 0.5% BSA, and 0.05% Tween 20 
(pH 3.2) at 37·C in 3 min, and were immediately neutralized with 
2.0 M Tris HCl (pH 7.5) to a final pH of 6.8. The isolated IgA was 
immediately applied to the BMZ of normal skin sections for the 
NAA. 
The negative control was performed by using an irrelevant band 
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Figure 1. Neutrophll adherence assay. Normal skin treated with anti-
BMZ antibody is used as substrate. A chamber surrounding the substrate 
is constructed allowing added neutrophils to be in the proximity of the 
BMZ-bound antibody. rGM-CSF is added to the neutrophils to activate 
the cells to upgrade their receptors for the antibody. Incubation allows 
neutrophlls to form pseudopods and stabilize BMZ binding. Unbound 
neutrophils are removed with PBS. 
from the same nitrocellulose blot and processed with LABD serum 
exactly as described above [37]. This elution was used as an addi-
tional control for the NAA. 
Preparation of Dapsone Solutions Dapsone (Aldrich Chemi-
cal Company, Inc., Milwaukee, WI) was dissolved in 0.032 N HCI 
(pH - 1.5) at 37°C for 5 h. The solution was then diluted 1: 10 
with sterile deionized H 20 and neutralized with 5 N and then 
0.5 N NaOH to a final pH of 7.3. The final concentration of the 
dapsone solution at pH 7.3 was 200 ,ug/ml. A diluent control was 
also prepared by neutralizing 1: 10-diluted 0.032 N HCI (pH -
1.5) with 5 N and then 0.5 N NaOH to a final pH of7 .3. Different 
dapsone concentration solutions were prepared by further diluting 
dapsone solution (200 J.lg/ml) in the diluent control. 
Indirect Immunofluorescence Indirect immunofluorescence 
was performed as described previously [37]. Briefly, 8-,um normal 
skin sections were cut on a cryostat microtome. After being incu-
bated with LABD antibody or BP serum (1 h for BP serum and 10 h 
for isolated LABD antibody), the skin sections were washed in PBS 
for 30 min and stained with fluorescein-conjugated anti-IgG di-
luted 1: 60 in PBS (Cappel Laboratories, Malvern, PA), gamma-
chain specific, or anti-IgA diluted 1: 80 in PBS (Cappel Laborato-
ries), alpha-chain specific, for 30 min, then washed with PBS. 
Specific binding of antibodies to the BMZ of skin sections was 
determined by epifluorescent microscopy. 
Neutrophil Adherence Assay (Fig 1) Four 10-mm sections of 
normal human skin 8,um in thickness were cryostat microtomed 
and placed on a sterile microscope slide in an area of2 cm2• The slide 
was air-dried for 15 min at 25 0 C then rinsed in PBS for 10 min to 
remove embedding medium. The skin sections were then incubated 
with isolated LABD antibody for 10 h (80 J.ll of undiluted elution 
per slide), or with BP serum for 1 h (80 J.ll ofBP serum diluted 1 : 20 
per slide), then washed three times in PBS for 10 min. A polypropyl-
ene chamber (produced by cutting off the top of the cap from a 5-ml 
cell culture tube) was used to surround the skin sections and was 
glued to the slide with clear nail polish. These slides were incubated 
at 37 ° C for 5 min before the assay, then 300 J.ll of neutrophil suspen-
sion were added per chamber followed by 30 J.ll of 5000 units/ml of 
rGM-CSF (Genzyme Corp., Boston, MA) to a final rGM-CSF con-
centration of aJ'proximately 0.5 nM. The specimen was then 
shaken rapidly (200 rpm) for five seconds. then slowly (100 rpm) 
for an additional 5 min at 37· C and then incubated for 30 min at 
37 0 C. The slides were finally washed by adding and then aspirating 
400-,u1 portions of sterile PBS until non-specific neutrophil adhe-
sion on the slide was removed. The incubation chamber was then 
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removed from the slide and cells were fixed with 37% formalde-
hyde for 5 min and then with ethanol for 10 min before staining 
with hematoxylin and eosin. This assay is an adaptation of the 
methods of Yamamoto et af (39J and Gammon et af [33J. The alter-
ation of the method of Gammon et af was primarily limited to the 
direct addition of rGM-CSF to the tissue sections after neutrophils 
had been added. In our hands binding was more specific and repro-
ducible under these conditions. 
Neutrophil adherence to the BMZ in normal skin treated with 
anti-BMZ IgA and IgG was determined using a light microscope 
equipped with a rotating linear micrometer. Average neutrophil 
adherence on 1 mm BMZ of skin sections of one slide was measured 
by counting the total number of neutrophils adhering to the BMZ 
of all four skin sections on that slide and dividing by the total BMZ 
length of all these skin sections. Results were calculated as the 
average neutrophil adherence per mm BMZ for each slide. The 
results done in triplicate (three slides prepared on the same day) 
were expressed as the mean number of neutrophils/mm BMZ 
(±SEM). 
Dose-Dependent Effect of Dapsone on Neutrophil Adher-
ence to IgA or IgG when Dapsone Was Added to Neutro-
phils For this series of experiments, neutrophils were treated with 
incremental doses of dapsone for 5 min before the neutrophils were 
added to substrate. Eighty microliters of solutions containing differ-
ent concentrations of dapsone were added to each 240-,u1 portion of 
neutrophil suspension. Each experiment was done in triplicate. 
Effect of Dapsone on LABD Anti-BMZ IgA To test the "in 
vivo" effect of dapsone on neutrophil adherence to IgA, neutrophil 
adherence to LABD antibody isolated from serum of a LABD pa-
tient, who was off dapsone for 11 d, was compared to neutrophil 
adherence to isolated LABD antibody from serum of the same pa-
tient on dapsone . Before LABD antibody isolation, the two sera 
were titered on human epidermis. 
Dose-Dependent Effect of Neutrophil Adherence to IgA 
when Dapsone Is Added to IgA To test the dose-dependent 
effect of Dapsone on neutrophil adherence to IgA when dapsone 
was a dded to IgA, LABD serum from a patient who was not on 
dapsone treatment was pre-treated with incremental doses of dap-
sone. LABD antibody from these serum specimens was isolated by 
Western blot nitrocellulose immunoaffinity. Isolated LABD anti-
body was reapplied to normal skin sections of three slides for each 
dapsone dose and the NAA was performed as described. 
The effect of dapsone on neutrophil adherence was expressed as 
percent inhibitio~. The mean percent inhibition between experi-
ments performed on different days was taken and expressed as mean 
(± SEM) percent inhibition. 
Neutrophil Adhesion to a Gelatin Matrix as a Viability Test 
for Dapsone-Treated Neutrophils The classical neutrophil ad-
hesion on gelatin matrix under the effect of platelet-activating fac-
tor (PAF) (Avanti Polar lipids, Inc., Birmingham, AL) was used to 
test the viability of neutrophils incubated with dapsone to rule out 
the possibility that dapsone was toxic to neutrophils in the concen-
tration used. The difference in percentage neutrophil adhesion to 
the gelatin matrix with and without PAF of the dapsone-untreated 
neutrophils was compared to that of dapsone-treated neutrophils. 
RESULTS 
Indirect Immunofluorescence and Neutrophil-Adherence 
Assay Initial studies involving direct incubation of whole LABD 
serum with 1 M NaCI split skin produced excellent binding to the 
BMZ. Binding to intact sections was minimal, probably because of 
the weakly exposed LABD antigens, and the relatively low titers of 
the specific IgA in these sera. However, LABD antibody bound well 
to the BMZ of intact skin if high titer Western blot immunoaffin-
ity-purified LABD antibody was used. This BMZ-bound IgA was 
found to be preferable for performing NAA. BP anti-BMZ antibody 
was of much higher titer and bound well to the BMZ of the intact 
skin when the skin was incubated directly with BP antiserum. 
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Table I. Summary of the Effect of Different Substrates and 
rGM-CSF on Neutrophil Adherence" 
Neutrophil 
Number Adherence 
Agonist Substrate of Sera IIF (PMNjmm) 
None Normal skin 0 0 0 
None Normal skin + normal 3 0 0 
serum 
None Normal skin + negative 2 0 0 
control elution 
None Normal skin + LABD 2 3+ 0 
antibody 
None Normal skin + BP 3 3+ 0 
antibody 
rGM-CSF Normal skin 0 o. 0 
rGM-CSF Normal skin + normal 3 0 0 
serum 
rGM-CSF Normal skin + negative 2 0 0 
control elution 
rGM-CSF Normal skin + LABD 2 3+ 100 ± 61 
antibody 
rGM-CSF Normal skin + BP 3 3+ 51 ± 21 
antibody 
• Each of these experiments was run a minimum of three times. Normal skin 
substrate (line 1) and rGM-CSF, normal skin, LABD antibody (line 9) were run daily 
as negative and positive controls, respectively. The results expressed here represent 
experiments for a single day with a given serum. Comparable results were obtained 
with the specified number of other sera tested. 
'Mean±SEM 
Therefore, it was unnecessary to purify BP antibody for the purpose 
of this study. 
Indirect immunofluorescence with isolated LABD IgA, the nega-
tive control elution from nitrocellulose, BP serum, or normal serum 
was performed with normal skin as a substrate. The results are 
summarized in Table 1. Normal skin pre-treated with isolated 
LABD antibody showed linear IgA deposition at the BMZ (Fig 2a). 
There was no evidence of IgG or IgM deposition. Normal skin 
pre-treated with BP serum showed linear IgG deposition, not IgA 
or IgM. No specific BMZ fluorescence was noted with control 
specimens (Fig 2b). 
The NAA was performed using normal skin alone or normal skin 
pre-treated with isolated LABD IgA, the negative control elution, 
BP serum, or normal serum, with or without rGM-CSF as an ago-
nist. The results are summarized in Table 1. Neutrophils bound at 
the BMZ were observed only when normal skin pre-incubated with 
isolated LABD antibody or BP serum was used as substrate concur-
rently in the presence of rGM-CSF (Fig 2c). The results indicate 
that rGM-CSF activated neutrophils bound specifically to the BMZ 
via the bound IgA or IgG, as has been previously reported [34,35J. 
There was no adherence of neutrophils to the BMZ when control 
elutions or normal serum was used and there was minimal non-spe-
cific binding (Fig 2d). 
Dose-Dependent Inhibition of Neutrophil Adherence to IgA 
when Dapsone Was Added to Neutrophils When dapsone 
was added directly to neutrophils before incubation with normal 
skin primarily treated with LABD antibody, a progressive decrease 
in neutrophil adherence to the BMZ (Fig 3a) and therefore a pro-
gressive increase in percent inhibition of neutrophil adherence (Fig 
3b) was observed as dapsone concentration was progressively in-
creased from 0 - 50 ,ug/ml. The standard error expressed in these 
experiments represents triplicate samples done on the same day. 
LABD antibody was isolated from the serum of a patient not taking 
dapsone. 
Expression of results in terms of percent inhibition allowed accu-
rate comparison of experiments performed on different days where 
the baseline number of neutrophils binding varied, but the fercent 
inhibition was comparable. The mean percent inhibition 0 differ-
ent doses of dapsone on neutrophil adherence to IgA on different 
days (n = 2) when dapsone is added to neutrophils is shown in Fig 4. 
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Figure 2. A) A photomicrograph showipg inctirect immunofluorescence 
of a normal skin section treated with isolated LABD antibody (magnifica-
tion X 250). Note linear IgA deposits at the BMZ. Similar results were 
obtained when normal skin was pre-treated with serum containing BP 
antibody and stained for IgG. B) Inctirect immunofluorescence stained for 
IgA when normal skin was treated with negative control elution . Similar 
negative IgA or IgG immunofluorescence results were also obtained 
when normal skin was pre-treated with random normal human serum. C) 
A photomicrograph of adherence of rGM-CSF stimulated neutrophils to 
the BMZ of normal skin pre-treated with LABD antibody. Similar results 
were obtained when normal skin pre-treated with serum containing BP 
antibody was used as substrate. Note specific neutrophil binding along 
the BMZ and rare or almost no non-specific binding of neutrophils in the 
epidermal and dermal areas. D) Absence of adherence of rGM-CSF-
stimulated neutrophils to the BMZ of normal skin pre-treated with the 
negative control elution of normal human serum. Similar results were 
obtained when LABD or BP antibodies bound to normal skin were incu-
bated with neutrophils in the absence of rGM-CSF. Note the absence of 
neutrophils along the BMZ, and rare non-specific binding of neutrophils 
in the dermal and epidermal areas. 
The minimal variability of inhibition on the same day (Fig 3b) or on 
different days (Fig 4) is illustrated. The inhibition curve has the 
shape of a saturation curve with a rapid increase of percent inhibi-
tion due to the effect of dapsone within serum concentration in 
standard pharmacologic range (0.1-10 J1g/ml), and a less rapid 
increase of inhibition (52-75%) in the range 10-50 mg/m [40]. 
"In vivo" Inhibitory Effect of Dapsone on Neutrophil Adher-
ence to IgA The LABD antibody of sera from the LABD patient 
who was on dapsone and subsequently off dapsone for 11 d were the 
same (1 : 80). There was a significant difference in neutrophi l adher-
ence produced by the two sera (Fig 5). Identical experiments on 
different days gave similar results . There was 42% inhibition of 
neutrophil adherence seen in the NAA using LABD antibody from 
the patient on dapsone compared to the NAA using LABD antibody 
from the patient off dapsone. Because the LABD antibody used was 
isolated from the serum by nitrocellulose immunoaffinity substrate 
after many washes before application to the normal skin, the results 
suggest that dapsone may affect neutrophil adherence by binding to 
the antibody molecule. 
Dose-Dependent Inhibition of Neutrophil Adherence to IgA 
when Dapsone Is Added to IgA There was a progressive de-
crease in neutrophil adherence to the BMZ of normal skin primarily 
treated with LABD antibody when the dapsone concentration previ-
ously added to the serum was progressively increased from 0 to 50 
J.Lg/ml, and a corresponding increase in percent inhibition of neu-
trophil adherence (Fig 6a,b). The mean dose-dependent percent 
inhibition of dapsone on neutrophil adherence to IgA in experi-
ments on three different days for two different LABD sera showed 
similar results with minimal variability in inhibition for different 
days. A saturation curve with rapidly increasing percent inhibition 
(0-60%) in the standard pharmacologic range (0-10 mg/ml), 
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Figure 3. The dose-dependent effect of dapsone on neutrophil adher-
ence to IgA when Dapsone is added to neutrophils. A shows a progressive 
decrease in neutrophil adherence to the BMZ of normal skin primarily 
treated with LABD antibody as dapsone concentration is progressively 
increased from 0 to 50 Ilg/ml. B expresses the same data as A as a function 
of percent inhibition. Expression of results in terms of percent inhibition 
allows accurate comparison of experiments performed on different days 
where the baseline number of neutrophils binding has varied. Note the 
rapid decrease of neutrophil adherence and therefore rapid increase of 
percent inhibition due to the effect of dapsone in standard pharmacologic 
range (0-10 Ilg/ml). Bars, SEM of three slides prepared in the same 
manner on the same day. The results expressed here represent a single 1-d 
experiment for one LABD serum. Similar results were obtained on differ-
ent days. 
which was similar to the one obtained when dapsone was added to 
neutrophils prior to incubation with substrate was also observed. 
This result suggests the possibility that dapsone may be exerting its 
effect on neutrophil adherence via a direct affect on IgA. Because 
the dapsone-pretreated antibody was washed prior to incubation 
with skin sections used as substrate for the NAA, there should have 
been no free dapsone present in the medium when the NAA was 
performcd. This makes it highly unlikely that thc inhibition effect 
of dapsone is on GM-CSF rather than on the antibody. 
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Figure 4. The mean percent inhibition of different doses of dapsone o~ 
neutrophil adherence to IgA on different days (n = 2) when dapsone IS 
added to neutrophils. Note the small SEM bars showing minimal variabil-
ity in inhibition for different days. The results expressed represent two 
experiments on two different days for two different LABD sera . 
For these experiments, we felt that it was essential that similar 
amounts of LABD antibody be isolated from serum specimens con-
taining incremental doses of dapsone to insure that the results were 
not related to the variability in antibody concentration. Conse-
quently, for these experiments nitrocellulose strip~ of the 97 kD 
antigen were all prepared on the same day from a slllgie epidermal 
extract prepared with identical running and transfer times. 
Dapsone Inhibition of Neutrophil Adherence to IgG Nor-
mal skin primarily treated with BP serum was used as substrate for 
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Figure 5. "I" vivo" effect of dapsone on neutrophil adherence to IgA. 
Substrates for NAA were normal skin pretreated with LABD antibody 
isolated from the same LABD patient who was on dapsone (100 mg/d) 
and subsequently off dapsone for 11 d . Both sera originally had a titer of 
1 : 80 IgA anti-BM2 antibody. The figure shows data from an experiment 
on one day. Bars, SEM of three slides prepared in the same manner on the 
same day. Identical experiments on different days gave similar results. 
Note the difference in neutrophil adherence between the two substrates. 
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Figure 6. The dose-dependent effect of dapsone on neutrophil adher-
ence to. lgA when ~apsone is added to IgA. A shows a progressive de-
crease m .neutrophil a<:llierence to the BM2 of normal skin primarily 
treated wI~h LABD antibody that was isolated from serum as dapsone 
concentration prevIOusly added to serum is progressively increased from 
~ t~ ~~ Jlg/ml. B expre:ses the same data as A as a function of percent 
mhibltion. Note the rapidly increasing percent inhibition in the standard 
pharmacolo~c range (0-10 Jlg/ml) as seen in Fig 3B. The results ex-
pressed here represent a single I-d experiment for one LABD serum. The 
mean dose-depend~nt percent inhibition of dapsone on neutrophil adher-
ence to IgA m e~p~nments on three different days for two different LABD 
sera showed sunilar results with minimal variability in inhibition for 
different days. 
th.e NAA, and dapsone was added to neutrophils before incubation 
~1~h the substrate. There was a progressive increase in percent inhi-
bitIOn (0-80%) when dapsone concentration added to neutrophils 
was progressively increased from 0 to 50 mg/ml, and the inhibition 
curve shape was similar to one seen in dapsone inhibition of neutro-
phil adherence to IgA. The mean dose-dependent percent inhibi-
tion of dapsone on neutrophil adherence to IgG on three different 
day experiments for three different BP sera showed similar result 
with minimal variability in inhibition for different days. 
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Effect of Dapsone on Neutrophil Viability Because of con-
cern that effects noted might be related to a toxic effect of dapsone 
or its diluent on neutrophils themselves, we evaluated the viability 
of neutrophils in these solutions using a separate index of neutrophil 
viability, adherence to a gelatin matrix. Neutrophils were treated 
with dapsone or its diluent before the evaluation of neutrophil ad-
hesion to gelatin matrix. There was an increase from 5% to 75% 
neutrophil adhesion to gelatin matrix observed when neutrophils 
were activated by PAF in both dapsone and the diluent control. 
There was no significant difference in the increase of percent neu-
trophil adhesion to gelatin matrix when neutrophils were activated 
with PAF in the absence or presence of dapsone (50 mg/ml) or 
diluent. It has also been shown previously that dapsone does not 
inhibit neutrophil chemotaxis or the phagocytic uptake ability of 
neutrophils [15]. 
DISCUSSION 
The deposition of IgA and subsequent accumulation of neutrophils 
is thought to be responsible for the inflammation and vesicle forma-
tion in DH and LABD. Dapsone produces clinical improvement in 
these disorders within 24-48 h, and the inflammatory process 
recurs within a similar time frame if the therapy is discontinued. 
Dapsone is not known to affect tissue antibody deposition and is 
believed to act via inhibition of the neutrophilic inflammatory pro-
cess [41] . The neutrophil-adherence assay using human skin was 
designed by Gammon as an in vitro method of evaluating the possi-
ble functional role of BP antibody in initiating the cellular inflam-
matory events observed at the BMZ in vivo [33] . We have found that 
dapsone inhibits this functional assay of antibody-neutrophil inter-
action in a dose-dependent manner for both IgG and IgA class BMZ 
antibodies. This inhibition may contribute to the clinical efficacy of 
dapsone in antibody-mediated diseases. 
We initially .confirmed the work of Hendrix who showed that 
rGM-CSF - activated neutrophils bind to BMZ-bound LABD anti-
body and IgA in the dermal papillary tips of dermatitis herpeti-
formis skin [35]. We were able to improve reproducibility in our 
laboratory by activating neutrophils with rGM-CSF after the neu-
trophils had been added to the chamber and were in proximity to the 
basement membrane - bound antibody. The absolute number of 
neutrophils binding per millimeter of basement membrane varied 
from day to day, probably secondary to variability in the quality of 
neutrophil isolation on that day. However, the modified technique 
was very reproducible within the same day and on different days 
when results were expressed as percent inhibition by dapsone, 
thereby correcting for variations in the absolute number of neutro-
phils bound in any given experiment. 
We were surprised to find that there was significantly less neu-
trophil adherence to basement membrane - bound antibody isolated 
from an LABD patient on dapsone treatment, compared to antibody 
isolated from an identical titered serum from the same patient off 
dapsone. This result was reproducible on multiple occasions. Con-
sequently, we pursued in vitro experiments to evaluate the effect of 
dapsone on the LABD antibody itself. There was a dose-dependent 
decrease in neutrophil adherence when antibody was pre-treated 
with dapsone. Because the process of antibody isolation from nitro-
cellulose completely isolated the specific antibody away from the 
medium, the decremental neutrophil adherence noted is likely due 
to a direct effect of dapsone on the antibody molecule. Further 
experiments investigating this interaction are underway. 
The exact mechanism by which dapsone is effective in the treat-
ment of IgA dermatoses is still uncertain. Dapsone has been shown 
to have an inhibitory effect on specific neutrophil functions includ-
ing lysosomal enzyme activity. myeloperoxidase-mediated iodina-
tion, and the generation of active oxygen metabolites in the neutro-
phil [15,17.18]. However. it seems unlikely that these mechanisms 
are central to the effect of dapso'ne because an inhibition of such 
functions would not be expected to influence the accumulation of 
neutrophils in tissue as is seen in dapsone-treated dermatoses. Dap-
sone has also been found to have an effect on chemotaxis, which 
would more readily explain the inhibition of neutrophil accumula-
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tion in tissue seen clinically [25,42]. Booth and co-workers have 
recently presented data showing that dapsone inhibits neutrophil 
adherence mediated by integrins [26]. This mechanism would pre-
sumably regulate the extravasation of neutrophils from blood ves-
sels by affecting binding to endothelial cells. Our findings suggest a 
mechanism by which neutrophils that have previously egressed 
from the vascular system might bind to tissue fixed antibody. Be-
cause IgA deposition in tissue is likely to be a necessary condition for 
the development of cutaneous lesions in IgA dermatoses. it may be 
that adherence of neutrophils to IgA is necessary for the localization 
of neutrophils and subsequent evolution of the skin lesion. The 
inhibition of neutrophil adherence by dapsone may therefore be an 
important therapeutic mechanism in the therapy ofIgA dermatoses. 
The mechanism by which dapsone inhibits neutrophil adherence 
to antibody is unclear. Neutrophil binding to antibody is believed to 
be mediated by Fe receptors on neutrophils [27] . Our results suggest 
that dapsone may exert its effect on the antibody itself. It is possible 
that dapsone may bind to the Fc portion of IgA, induce some con-
formational changes. and block neutrophil binding. The influence 
of additional potential mechanisms such as inhibition of the expres-
sion of neutrophil Fe receptors or inhibition of binding of the recep-
tor to IgA, cannot be excluded. The Fc portion ofIgA has also been 
shown to be important in the IgA-induced chemokinesis of neutro-
phils. in which IgA enhances the f-met-Ieu-phe-induced chemo-
taxis of neutrophils [43]. Finally. our in vitro results show that dap-
sone also inhibits neutrophil adherence to IgG in a dose-response 
manner. These results may explain the mechanism of dapsone in the 
treatment of some cases in BP and in other IgG-neutrophil-
mediated diseases. 
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